Prostate Cancer Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Pomegranate Juice or Extract on Rising Prostate-Specific Antigen Levels in Men Following Primary Therapy for Prostate Cancer
Primary Objective:
To compare the effects of daily consumption of pomegranate liquid extract, and placebo on
end-of-treatment (52 weeks) prostate-specific antigen (PSA) doubling time in male subjects
who have rising serum PSA levels after primary therapy for localized prostate cancer.
Secondary Objectives:
1. To determine the effect of the pomegranate treatments on the change in serum PSA
doubling time from baseline to end-of-treatment.
2. To evaluate the effects of the pomegranate treatments on changes in the health-related
quality of life (QOL)
3. To determine the time to tumor recurrence
4. To assess the tolerability and toxicity of the pomegranate treatments
5. To determine the effect of the pomegranate treatments on response rates for positive
serum PSA doubling times and for declining post-treatment serum PSA levels (negative
doubling times)
Some studies suggest that diets with certain plant-based sources (plant chemicals) may help
to reduce the risk of diseases, such as cancer and heart disease.
Pomegranate liquid extract is identical to pomegranate juice, but has a higher concentration
of ingredients that are known to prevent damage to cells.
The placebo used in this study is a juice made by the study sponsor that looks and tastes
like pomegranate liquid extract, but it does not have active ingredients, such as plant
chemicals.
Before beginning screening for this study, you will be checked to make sure you do not have
any allergic reaction to pomegranate liquid extract. You will be asked to drink one 4-ounce
(1/2 cup) sample of pomegranate juice, mixed with pomegranate liquid extract, and placebo.
You will then be watched by the study staff for about 30 minutes. If any signs and symptoms
of allergic reactions are seen, appropriate medical attention will be provided, and you will
not be able to proceed to the screening for this study. If you do not experience any signs
of symptoms of allergic reactions, you will proceed to the screening for this study.
Before you can start on this study, you will have "screening tests." These tests will help
the doctor decide if you are eligible to take part in this study. You will have your
complete medical history recorded. You will have a physical exam, including measurement of
your vital signs (blood pressure, heart rate, temperature, and breathing rate), height, and
weight. You will have a digital (insertion by a finger) rectal exam. You will be asked to
complete a food-frequency questionnaire, which will ask about what types of fruits and
vegetables you eat and how often you eat them. It will take about 20 minutes to complete.
You will also have a quality-of-life (QOL) questionnaire that will ask about your health,
activities that might be affected by your health, and/or about pain that you have recently
had. It will take about 15 minutes to complete this questionnaire.
If you have diabetes and have not had your blood sugar levels tested in the past 3 months,
you will have blood drawn (about 1 tablespoon) to check your HbA1c (which will show your
blood sugar levels).
If you are found to be eligible to take part in this study, you will be randomly assigned
(as in the toss of a coin) to 1 of the 2 study groups (pomegranate liquid extract or
placebo). Participants in one group will receive pomegranate liquid extract. Participants in
the other group will receive placebo. There will be a 2 out of 3 chance that you will
receive pomegranate liquid extract.
You will be notified by telephone call about 7 days after your screening visit that you are
eligible to take part in the study. You will also be told the delivery date for your study
juice and a study-product diary.
This is a double-blinded study, which means that neither you nor your doctor or any medical
staff involved in your care, will know which product you receive until the study is
complete. However, the study doctor can find out which product you are receiving (if there
is an emergency or if it is necessary to know for your health).
The study drink will be shipped to M. D. Anderson and then shipped to you directly from M.
D. Anderson. It should be refrigerated immediately when you receive it. You will drink an
8-ounce (1 cup) pomegranate liquid extract or placebo each day (7 days a week) for 52 weeks
(about 1 year). All bottles of the study drink should be refrigerated until you are ready to
drink it. You will receive detailed instructions on how to drink the study drink when you
receive your first week's supply. You will continue to drink the study drink for 52 weeks or
until your PSA levels do not appear to be responding.
A telephone call will be made approximately 7 days after your screening visit. At this time,
you will be informed of your eligibility to participate in the study, and that you have been
randomized. You will be informed of the delivery date for your study drink and a
study-product consumption diary.
During this study, you will be asked to return to the clinic every 13 weeks (Weeks 13, 26,
39, and 52). You will see the research nurse at Weeks 13, 26, and 39, and you will see the
study doctor at Week 52. During these visits, you will have a physical exam, including
measurement of your vital signs and weight. You will be asked if you are taking any
medications. You will have blood drawn (about 3 to 4 teaspoons) and urine collected for
routine tests. You will be asked if you have been drinking the study drink each day. You
will be given a study-product consumption diary with instructions to record that you drank
the drink daily. It will be given to you at each 13-week follow-up visit. You will be asked
not to begin or to stop taking any new nutritional or dietary supplements while you are on
this study so that your supplements do not interfere with the effects of the study drink.
If the disease gets worse while you are on study, you and your study doctor will be able to
find out which study group you were in. If you were taking the placebo, you may be eligible
to enter into another study where you will receive the pomegranate extract for up to 12
months.
During your last study visit (Week 52), you will have a physical exam, including measurement
of your vital signs and weight. You will have a digital rectal exam. You will be asked about
any medications you may be taking. You will have blood drawn (about 3 to 4 teaspoons) and
urine collected for routine tests. You will be asked if you have been drinking the study
drink each day for the last 13 weeks of the study (your consumption diary will be reviewed).
You will be given another food-frequency questionnaire and QOL questionnaire like the ones
that were given during screening.
This is an investigational study. Up to 200 participants will take part in this multicenter
study. Up to 40 will be enrolled at M. D. Anderson.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
| Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
| Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
| Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
| Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
| Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
| Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
| Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
| Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |